Proteasome Inhibitors: Recent Progress and Future Directions
暂无分享,去创建一个
[1] D. Filippov,et al. Acetylene functionalized BODIPY dyes and their application in the synthesis of activity based proteasome probes. , 2007, Bioorganic & medicinal chemistry letters.
[2] H. Ovaa,et al. Profiling proteasome activity in tissue with fluorescent probes. , 2007, Molecular pharmaceutics.
[3] S. Demo,et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. , 2007, Cancer research.
[4] H. Overkleeft,et al. A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome. , 2007, Bioorganic & medicinal chemistry letters.
[5] K. Kim,et al. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. , 2007, Chemistry & biology.
[6] W. Koltun,et al. Enhanced Intestinal Expression of the Proteasome Subunit Low Molecular Mass Polypeptide 2 in Patients with Inflammatory Bowel Disease , 2007, Diseases of the colon and rectum.
[7] M. Groll,et al. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. , 2007, Chemical reviews.
[8] M. Bogyo,et al. Tagging and detection strategies for activity-based proteomics. , 2007, Current opinion in chemical biology.
[9] Guoqing Shi,et al. The Tumor Proteasome Is a Primary Target for the Natural Anticancer Compound Withaferin A Isolated from “Indian Winter Cherry” , 2007, Molecular Pharmacology.
[10] D. Filippov,et al. A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. , 2006, Chemistry & biology.
[11] T. Hunter,et al. Proteasome inhibitor drugs on the rise. , 2006, Cancer research.
[12] W. Koltun,et al. Dextran Sulfate Sodium-Induced Colitis Is Associated with Enhanced Low Molecular Mass Polypeptide 2 (LMP2) Expression and Is Attenuated in LMP2 Knockout Mice , 2006, Digestive Diseases and Sciences.
[13] D. McConkey,et al. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia , 2006, Molecular Cancer Therapeutics.
[14] Di Chen,et al. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. , 2006, Cancer research.
[15] R. Huber,et al. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. , 2006, Journal of the American Chemical Society.
[16] C. Xia,et al. INVESTIGATION OF DRUG-DRUG INTERACTION POTENTIAL OF BORTEZOMIB IN VIVO IN FEMALE SPRAGUE-DAWLEY RATS AND IN VITRO IN HUMAN LIVER MICROSOMES , 2006, Drug Metabolism and Disposition.
[17] A. Goldberg,et al. Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate* , 2006, Journal of Biological Chemistry.
[18] D. Soejarto,et al. Biodiversity as a source of anticancer drugs. , 2006, Current drug targets.
[19] Kinneret Keren,et al. Dynamic imaging of protease activity with fluorescently quenched activity-based probes , 2005, Nature chemical biology.
[20] J. Yewdell,et al. Immunoproteasomes: regulating the regulator. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[21] Di Chen,et al. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. , 2005, Biochemical pharmacology.
[22] K. Anderson,et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib , 2005, Nature Methods.
[23] N. Munshi,et al. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. , 2004, Blood.
[24] Di Chen,et al. Green tea and tea polyphenols in cancer prevention. , 2004, Frontiers in bioscience : a journal and virtual library.
[25] K. Daniel,et al. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. , 2003, Biochemical pharmacology.
[26] T. Mincer,et al. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. , 2003, Angewandte Chemie.
[27] J. Adams. Development of the proteasome inhibitor PS-341. , 2002, The oncologist.
[28] H. Naganawa,et al. Isolation and structural determination of phepropeptins A, B, C, and D, new proteasome inhibitors, produced by Streptomyces sp. , 2001, The Journal of antibiotics.
[29] H. Ploegh,et al. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. , 2001, Chemistry and Biology.
[30] R. Huber,et al. Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. , 2001, Journal of molecular biology.
[31] C. Crews,et al. The ubiquitin‐proteasome pathway and proteasome inhibitors , 2001, Medicinal research reviews.
[32] David M. Smith,et al. Ester Bond-containing Tea Polyphenols Potently Inhibit Proteasome Activity in Vitro and in Vivo * , 2001, The Journal of Biological Chemistry.
[33] M. Bogyo,et al. Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] P. Kloetzel,et al. Ubiquitin and proteasomes: Antigen processing by the proteasome , 2001, Nature Reviews Molecular Cell Biology.
[35] K. Lindsten,et al. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. , 2001, Molecular cell.
[36] A. Ciechanover,et al. The ubiquitin system , 2000, Nature Medicine.
[37] S. Ōmura,et al. Separation of cathepsin A-like enzyme and the proteasome: evidence that lactacystin/beta-lactone is not a specific inhibitor of the proteasome. , 2000, The international journal of biochemistry & cell biology.
[38] R. Deshaies,et al. A Proteasome Howdunit The Case of the Missing Signal , 2000, Cell.
[39] A. Ciechanover,et al. Ubiquitin‐mediated proteolysis: biological regulation via destruction , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.
[40] Kohei Takahashi,et al. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities. , 2000, The Journal of antibiotics.
[41] M. Kuroda,et al. Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei sacc. TC 1093. , 2000, The Journal of organic chemistry.
[42] R. Huber,et al. Crystal Structure of Epoxomicin:20S Proteasome reveals a molecular basis for selectivity of alpha,beta-Epoxyketone Proteasome Inhibitors , 2000 .
[43] M. Groll,et al. Synthesis of bivalent inhibitors of eucaryotic proteasomes , 2000, Journal of peptide science : an official publication of the European Peptide Society.
[44] K. Takahashi,et al. TMC-86A, B and TMC-96, new proteasome inhibitors from Streptomyces sp. TC 1084 and Saccharothrix sp. TC 1094. II. Physico-chemical properties and structure determination. , 1999, The Journal of antibiotics.
[45] C. Crews,et al. Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α', β'-epoxyketones , 1999 .
[46] C. Crews,et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[47] C. Crews,et al. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. , 1999, Bioorganic & medicinal chemistry letters.
[48] C. Crews,et al. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. , 1999, Cancer research.
[49] R. Huber,et al. Bivalency as a principle for proteasome inhibition. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[50] A. Harvey,et al. Medicines from nature: are natural products still relevant to drug discovery? , 1999, Trends in pharmacological sciences.
[51] R. Huber,et al. Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. , 1999, Chemistry & biology.
[52] C. Crews,et al. Eponemycin analogues: syntheses and use as probes of angiogenesis. , 1998, Bioorganic & medicinal chemistry.
[53] Sunny Shin,et al. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. , 1998, Chemistry & biology.
[54] L. Dick,et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. , 1998, Bioorganic & medicinal chemistry letters.
[55] P. Weber,et al. Rational design of boropeptide thrombin inhibitors: beta, beta-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profile. , 1998, Bioorganic & medicinal chemistry letters.
[56] A. Goldberg,et al. Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[57] S. Ōmura,et al. Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. , 1997, Biochemical and biophysical research communications.
[58] R. Huber,et al. Structure of 20S proteasome from yeast at 2.4Å resolution , 1997, Nature.
[59] L. Dick,et al. Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin in Cultured Cells* , 1997, The Journal of Biological Chemistry.
[60] Marc W. Kirschner,et al. How Proteolysis Drives the Cell Cycle , 1996, Science.
[61] Wei Chen,et al. The Antitumor Drug Aclacinomycin A, Which Inhibits the Degradation of Ubiquitinated Proteins, Shows Selectivity for the Chymotrypsin-like Activity of the Bovine Pituitary 20 S Proteasome* , 1996, The Journal of Biological Chemistry.
[62] J. Leban,et al. Design and Synthesis of Novel Protease Inhibitors. Tripeptide α′, β′-Epoxyketones as Nanomolar Inactivators of the Proteasome. , 1996 .
[63] J. Palmer,et al. Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. , 1996, The Biochemical journal.
[64] L. Dick,et al. Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin , 1996, The Journal of Biological Chemistry.
[65] A. Murzin,et al. A protein catalytic framework with an N-terminal nucleophile is capable of self-activation , 1995, Nature.
[66] J. Palmer,et al. Vinyl sulfones as mechanism-based cysteine protease inhibitors. , 1995, Journal of medicinal chemistry.
[67] R F Standaert,et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin , 1995, Science.
[68] R. Huber,et al. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. , 1995, Science.
[69] M. Figueiredo-Pereira,et al. A New Inhibitor of the Chymotrypsin‐Like Activity of the Multicatalytic Proteinase Complex (20S Proteasome) Induces Accumulation of Ubiquitin‐Protein Conjugates in a Neuronal Cell , 1994, Journal of neurochemistry.
[70] A. Goldberg,et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.
[71] M. Orlowski. The multicatalytic proteinase complex (proteasome) and intracellular protein degradation: diverse functions of an intracellular particle. , 1993, The Journal of laboratory and clinical medicine.
[72] T. Oki,et al. Epoxomicin, a new antitumor agent of microbial origin. , 1992, The Journal of antibiotics.
[73] S. Ōmura,et al. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. , 1991, The Journal of antibiotics.
[74] T. Oki,et al. Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity. , 1990, The Journal of antibiotics.
[75] M. Orłowski,et al. Evidence that Pituitary Cation‐Sensitive Neutral Endopeptidase Is a Multicatalytic Protease Complex , 1983, Journal of neurochemistry.
[76] M. Orłowski,et al. Inhibition of Rabbit Brain Prolyl Endopeptidase by N‐Benzyloxycarbonyl‐Prolyl‐Prolinal, a Transition State Aldehyde Inhibitor , 1983, Journal of neurochemistry.
[77] D. Chauhan,et al. A novel proteasome inhibitor NPI-0052 as an anticancer therapy , 2006, British Journal of Cancer.
[78] H. Overkleeft,et al. Chemical proteomics profiling of proteasome activity. , 2006, Methods in molecular biology.
[79] R. Orlowski. The ubiquitin proteasome pathway from bench to bedside. , 2005, Hematology. American Society of Hematology. Education Program.
[80] C. Crews,et al. Natural Product and Synthetic Proteasome Inhibitors , 2004 .
[81] A. Goldberg,et al. Proteasome inhibitors: from research tools to drug candidates. , 2001, Chemistry & biology.
[82] M. Karin,et al. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.
[83] J. Rouvinen,et al. Structural comparison of Ntn‐hydrolases , 2000, Protein science : a publication of the Protein Society.
[84] M. Figueiredo-Pereira,et al. Synthetic inhibitors of the multicatalytic proteinase complex (proteasome). , 1993, Enzyme & protein.
[85] C. Cardozo,et al. Catalytic components of the bovine pituitary multicatalytic proteinase complex (proteasome). , 1993, Enzyme & protein.